The numbers make that impossible to ignore. Chronic and mental health conditions account for 90% of U.S. healthcare spending, according to the CDC. Cardiovascular disease and its risk factors are on track to become a trillion-dollar cost crisis.
That’s right.
Obesity affects at least one in four adults in every state. And yet, when employer and health plan leaders gather around the table, the conversation too often boils down to a single question:
“Do we cover the medication?”
The risks hiding in plain sight
GLP-1s may be clinically powerful, but access without clinical oversight and wraparound support is a risk disguised as a solution. Real-world discontinuation rates are strikingly high, as high as 65% at the one-year mark. And when therapy stops without a thoughtful plan, the consequences extend far beyond weight gain.
Hard-won cardiometabolic gains erode, and health risks can rise and return in dangerous patterns.
For many people, the end of a prescription becomes the beginning of a new downward spiral.
For employers and benefits leaders, this is the threat hiding in plain sight. It is a high-cost medication strategy operating without a longitudinal care model to support it. The result isn’t just wasted spend; it’s destabilized health, fragmented care, increased clinical risk, and downstream consequences that show up at work, at home, and across entire families.
Deprescribing does not equal cost control
One of the most dangerous mistakes employers and health plans can make is to treat deprescribing as an administrative lever.
A prior authorization expires. A coverage rule changes. A member switches plans. A cost threshold is reached. Suddenly, a medication once framed as clinically necessary becomes financially inconvenient.
But chronic conditions do not disappear just because benefit design seems logical.
When therapy stops abruptly, the clinical gains achieved over months can unravel quickly. Blood pressure rises, appetite regulation shifts, and glycemic control worsens. Weight gain doesn’t always return benignly; it frequently accumulates in areas that carry severe metabolic and cardiovascular risk.
That doesn’t mean every patient should stay on every medication forever. But it begs a fundamental question that benefits leaders need to ask:
What is the point of investing thousands in GLP-1s if the primary goal is to force patients off them a few months later?
An “exit strategy” is not a strategy at all
An ultimate goal of ceasing medication therapy was not how GLP-1s were designed to work. In fact, that is not how any chronic disease medication has ever worked. We don’t put a patient on blood pressure or cholesterol medication with the sole intent of pulling the rug out as soon as their numbers improve. Chronic conditions require chronic management.
When you treat a longitudinal therapy like a short-term intervention, you aren’t saving money. You are simply paying top dollar for a temporary delay in clinical risk.
Real cardiometabolic care requires the infrastructure around the prescription.
Continuous clinical monitoring, behavioral and lifestyle integrations such as nutrition and physical activity, and transition planning to establish intentional protocols instead of administrative cutoff dates are essential in creating health and cost outcomes for those patients who are on medications.
A program that can start or stop a drug but cannot responsibly monitor, adjust, or support the human being taking it isn’t managing cardiometabolic health. It is managing a transaction.
And when the transaction ends, the risk does not.
A better mandate
Employers often view cardiometabolic health through claims data: pharmacy spend, medical trend, and utilization. Those absolutely matter, but claims data doesn’t capture the full cost of getting this wrong.
A narrow GLP-1 strategy may appear financially disciplined on paper while simply shifting risk elsewhere: to the employee, the spouse, the caregiver, the manager, and eventually back to the claims line.
Benefits leaders cannot afford to view this as a medication coverage debate. The mandate is to build a model of care that is clinically responsible before, during, and after medication use.
That means demanding more from vendors, health plans, and clinical partners:
Primary Care Reconnection: Integrating care back into the patient’s primary baseline rather than isolating them in a digital silo.
Appropriate Prescribing Criteria: Ensuring the right medication goes to the right patient at the right time, not just to those who can request it.
Active Monitoring & Tapering Protocols: Managing side effects, blood pressure, and metabolic markers in real time.
Wraparound Behavioral Support: Pairing therapy with nutrition, movement, and stress management tools that build long-term habits.
The next era of cardiometabolic benefits cannot be built around a “miracle-drug mindset.” It must be built around clinical stewardship, continuity, equity, and accountability.
GLP-1s may be part of the answer. But they are not the strategy. The strategy is what surrounds them.
